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examinations of postprocedural change of BW with cor-
relation to Hct may help to clarify this issue.
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Reply from the Authors
We read with interest the letter from Lai et al [1], and
we thank them for their interest in our study [2]. The
authors raise the question that the association between
contrast-induced nephropathy (CIN) and drop in hema-
tocrit after percutaneous coronary intervention found
in our study might be explained by a greater extent of
hemodilution and, consequently, lower hematocrit in pa-
tients with CIN. While accepting this point of view as a
plausible explanation of our finding, we consider that this
does not deny the role of procedure-related blood loss in
the genesis of CIN. Lai et al reasonably state that, based
on the described calculations, the blood loss should be as
much as 510 mL to cause the observed change in hema-
tocrit level. Though the accurate amount of blood loss
cannot be assessed retrospectively, a higher drop in hema-
tocrit in our study was associated with significantly higher
rates of hemorrhagic complications and blood product
transfusion (data not published), supporting the role of
blood loss in the genesis of CIN (see Table 1).
As we mention in the Discussion section of the
manuscript, a more significant drop in hematocrit may
also be attributed to the higher incidence of periproce-
dural hypotension (due to bleeding and/or hemodynamic
instability), and to subsequent hemodilution following
more intensive fluid replacement therapy. We certainly
support the idea of periprocedural monitoring of body
weight in patients undergoing contrast medium exposure;
this should be part of the comprehensive approach to elu-
cidate the relation between drop in hematocrit and CIN,
Table 1. Incidence of access site hematoma and blood transfusion in
relation to drop in hematocrit
Quintiles of drop in hematocrit %
>2.2 to >3.9 to >5.4 to P
≤2.2 ≤3.9 ≤5.4 ≤7.4 >7.4 value
Hematoma % 4.1 4.6 5.4 7.3 23.0 ≤0.0001
Transfusion % 1.3 1.3 2.4 2.5 17.7 ≤0.0001
along with data on periprocedural hemodynamics, hydra-
tion volume, and urine output.
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PAI-1 in diabetic nephropathy
To the Editor: The mechanisms by which plasminogen
activator inhibitor-1 (PAI-1), the main plasminogen acti-
vator inhibitor, promotes fibrosis in a number of exper-
imental models, are still intensely debated. On the one
hand, PAI-1 is supposed to inhibit extracellular matrix
degradation by preventing plasmin formation. On the
other hand, it has been shown to prevent transforming
growth factor (TGF) beta activation and, thus, to pre-
vent extracellular matrix production [1]. Nicholas et al
recently provided experimental, in vivo data suggesting
that PAI-1 deficiency might be helpful in the prevention
of diabetic nephropathy: when compared to wild-type an-
imals, PAI-1 knockout mice have, thus, a lower urinary
albumin excretion and a lower synthesis of fibronectin
in the kidney after streptozotocin injection [2]. Interest-
ingly, PAI-1 is reported by these authors to enhance TGF
beta synthesis by mesangial cells, a finding that is some-
what provocative because TGF beta is itself a potent en-
hancer of the PAI-1 promoter gene, and because recent
works by Luttun et al and our group demonstrated that
PAI-1 plays a critical role in the regulation of the TGF
beta activation (i.e., PAI-1 inhibits TGF-beta activation)
[3, 4]. Moreover, in Nicholas’ study, the induction of TGF-
beta synthesis, at the mRNA and at the protein level, in
